Share

August 2015; 1 (2) EditorialOpen Access

Next-generation sequencing still needs our generation's clinicians

A. Reghan Foley, Sandra Donkervoort, Carsten G. Bönnemann
First published August 13, 2015, DOI: https://doi.org/10.1212/NXG.0000000000000019
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
922

Share

Article Information

vol. 1 no. 2 e13
DOI: 
https://doi.org/10.1212/NXG.0000000000000019
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • First Published August 13, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. A. Reghan Foley, MD*,
    2. Sandra Donkervoort, MS, CGC* and
    3. Carsten G. Bönnemann, MD
  1. A. Reghan Foley, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel funding from a non-profit patient organization, “Cure CMD,” (on one occasion) to attend a “Cure CMD” meeting; European Neuromuscular Centre and Muscular Dystrophy UK

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. I am an employee of the National Institutes of Health (NIH)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

    Non-financial disclosures:

    1. NONE

  2. Sandra Donkervoort, MS, CGC* and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

    Non-financial disclosures:

    1. NONE

  3. Carsten G. Bönnemann, MD
    4. Scientific Advisory Boards:

    1. Scientific Advisory Board (1) Cure CMD, non-profit entity (2) RYR1 Foundation, non-profit entity (3) BioMedical Research (4) BioMarin Pharmaceutical (5) Third Rock Ventures (6) Audentes Therapeutics

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Has received travel expenses and/or honoraria for lectures or educational activities not funded by industry

    Editorial Boards:

    1. Co-Editor-in-Chief: Journal of Neuromuscular Disease

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Principal investigator of the CALLISTO trial sponsored by Santhera Pharmaceuticals

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. I am an employee of the NIH and all my research funding is from intramural NIH resources

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

    Non-financial disclosures:

    1. NONE

  1. From the Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD.
  1. Correspondence to Dr. Bönnemann: carsten.bonnemann{at}nih.gov

Article usage

Article usage: August 2015 to November 2023

AbstractFullPdfSource
Aug 2015496558165Highwire
Sep 20159762031Highwire
Oct 201510512039Highwire
Nov 2015144912Highwire
Dec 2015202814Highwire
Jan 2016223814Highwire
Feb 2016191911Highwire
Mar 2016352221Highwire
Apr 2016252618Highwire
May 2016253111Highwire
Jun 201615717Highwire
Jul 2016142220Highwire
Aug 201619104Highwire
Sep 201621138Highwire
Oct 20167116Highwire
Nov 201610144Highwire
Dec 201619197Highwire
Jan 201714155Highwire
Feb 201715236Highwire
Mar 201726323Highwire
Apr 20179218Highwire
May 20171100Highwire
Jun 2017953Highwire
Jul 2017983Highwire
Aug 2017972Highwire
Sep 20171299Highwire
Oct 20171036Highwire
Nov 2017935Highwire
Dec 20173136Highwire
Jan 2018588Highwire
Feb 20181122Highwire
Mar 20187117Highwire
Apr 20186153Highwire
May 20181141Highwire
Jun 20182175Highwire
Jul 20184314Highwire
Aug 20184153Highwire
Sep 201833654Highwire
Oct 201844967Highwire
Nov 201845223Highwire
Dec 2018067114Highwire
Jan 201991769Highwire
Feb 201986011Highwire
Mar 20194184Highwire
Apr 20196263Highwire
May 20194148Highwire
Jun 201972610Highwire
Jul 201914466Highwire
Aug 2019394Highwire
Sep 201910124Highwire
Oct 20191080Highwire
Nov 20199165Highwire
Dec 20191116Highwire
Jan 20209123Highwire
Feb 20205116Highwire
Mar 2020999Highwire
Apr 2020199Highwire
May 202021010Highwire
Jun 202021112Highwire
Jul 202031411Highwire
Aug 202011311Highwire
Sep 2020710510Highwire
Oct 20203423Highwire
Nov 202022110Highwire
Dec 20205142Highwire
Jan 20211204Highwire
Feb 20212116Highwire
Mar 20213119Highwire
Apr 20212135Highwire
May 20212834Highwire
Jun 20215156Highwire
Jul 2021268Highwire
Aug 2021142Highwire
Sep 2021375Highwire
Oct 202131417Highwire
Nov 20210515Highwire
Dec 2021187Highwire
Jan 2022164Highwire
Feb 2022375Highwire
Mar 20221157Highwire
Apr 2022242Highwire
May 20222107Highwire
Jun 2022097Highwire
Jul 2022142Highwire
Aug 2022132Highwire
Sep 202221711Highwire
Oct 202251813Highwire
Nov 202215720Highwire
Dec 20221185Highwire
Jan 202303313Highwire
Feb 20230155Highwire
Mar 20234112Highwire
Apr 2023071Highwire
May 2023129Highwire
Jun 20233144Highwire
Jul 20230210Highwire
Aug 2023144Highwire
Sep 20233208Highwire
Oct 2023290Highwire
Nov 20230188Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles